Publication Details
Abstract
Metabolic syndrome (MetS) is a multifaceted clinical condition characterized by a cluster of metabolic abnormalities, including central obesity, insulin resistance, hypertension, dyslipidemia, and glucose intolerance. It significantly increases the risk of developing cardiovascular diseases and type 2 diabetes mellitus. The biochemical implications of MetS are profound, involving alterations in lipid metabolism, chronic low-grade inflammation, oxidative stress, and hormonal imbalances. These disturbances are often reflected in biomarkers such as elevated fasting glucose, increased triglycerides, decreased HDL cholesterol, high levels of C-reactive protein (CRP), and insulin resistance markers like HOMA-IR. Early detection of MetS is crucial for preventing its progression and associated complications. Biochemical screening provides a valuable tool for identifying at-risk individuals before clinical symptoms become evident. Recent research emphasizes the role of adipokines, pro-inflammatory cytokines (such as TNF-α and IL-6), and oxidative stress markers as early indicators of metabolic dysfunction. Additionally, advances in genomics and metabolomics have enhanced our understanding of the pathophysiological mechanisms underlying MetS, offering promising avenues for personalized intervention strategies. This review highlights the importance of integrating biochemical markers in routine clinical assessments for early identification of MetS. Understanding the interplay between metabolic pathways and biochemical alterations can aid in developing more targeted therapeutic approaches. Ultimately, early biochemical diagnosis, combined with lifestyle modification and pharmacological interventions, may reduce the global burden of metabolic syndrome and its life-threatening sequelae.